New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
06:11 EDTBCRXBioCryst reports Q4 EPS (22c), consensus (16c)
Reports Q4 revenue $4.1M, consensus $4.02M.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use